Interleukin-10 and Interleukin-12 Modulation in Patients with Relapsing-Remitting Multiple Sclerosis on Therapy with Interferon-beta 1a: Differences in Responders and Non Responders

REFERENCES

• J.L. Trotter, K.G. Collins, and R.C. van der Veen. 1991. Serum cytokine levels in chronic progressive multiple sclerosis: Interleukin-2 levels parallel tumor necrosis factor-alpha levels. J. Neuroimmunol. 33 (1):29–36.
   PubMedGoogle Scholar
• K. Balashov, D. Smith, S. Khoury, D.A. Hafler, and H.L. Weiner. 1997. Increased interleukin-12 production in progressive multiple sclerosis: Induction by activated CD4+ T cells via CD40 ligand. Proc. Natl.Acad. Sci. U S A. 94 (2):599–603.
   PubMedGoogle Scholar
• H. Link. 1998. The cytokine storm in multiple sclerosis. Mult. Sclerosis 4 (1):12–5.
   PubMedGoogle Scholar
• J.J. Graber, D. Ford, M. Zhan, G. Francis, H. Panitch, and S. Dhib-Jalbut. 2007. Cytokine changes during IFNbeta-1a therapy in multiple sclerosis: Correlations with IFNbeta-1a dose and MRI response. J. Neuroimmunol. 185 (1–2):168–74.
   PubMedGoogle Scholar
• J.F. Kurtzke. 1983. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 33 (11):1444–52.
   PubMed Web of Science ®Google Scholar
• K. Makhlouf, H. Weiner, and S. Khoury. 2001. Increased percentage of IL- 12+ monocytes in the blood correlates with the presence of active MRI lesions in MS. J. Neuroimmunol. 119 (1):145–9.
   PubMedGoogle Scholar
• J. Imitola, T. Chitnis, and S.J. Khoury. 2005. Cytokines in multiple sclerosis: From bench to bedside. Pharmacol. Ther. 106 (2):163–177.
   PubMedGoogle Scholar
• H.F. Petereit, R. Pukrop, F. Fazekas, S.U. Bamborschke, S. Röpele, H.W. Kölmel, S. Merkelbach, G. Japp, P.J. Jongen, H.P. Hartung, and O.R. Hommes. 2003. Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis. J. Neurol. Sci. 206 (2):209–14.
   PubMedGoogle Scholar
• H.H. Salama, O.J. Kolar, Y.C. Zang, and J. Zhang. 2003. Effects of combination therapy of IFNbeta-1a and prednisone on serum immunologic markers in patients with multiple sclerosis. Mult. Sclerosis 9 (1):28–31.
   PubMedGoogle Scholar
• M.E. Kozovska, J. Hong, Y.C. Zang, S. Li, V.M. Rivera, J.M. Killian, and J.Z. Zhang. 1999. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 53 (8):1692–7.
   PubMedGoogle Scholar
• M.H. Rep, R.Q. Hintzen, C.H. Polman, and R.A. van Lier. 1996. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 67 (2):111–8.
   PubMedGoogle Scholar
• R.A. Rudick, R.M. Ransohoff, R. Peppler, S. Vanderbrug Medendorg, P. Lehmann, and J. Alan. 1996. Interferon beta induces interleukin-10 expression: Relevance to multiple sclerosis. Ann. Neurol. 40 (4):618–27.
   PubMedGoogle Scholar
• A.J. Fahey, R.A. Robins, and C.S. Constantinescu. 2007. Reciprocal effects of IFN-beta and IL-12 on STAT4 activation and cytokine induction in T cells. J. Leukoc. Biol. 81 (6):1562–7.
   PubMedGoogle Scholar
• G. Francis, F. Weber, and P. Rieckmann. 2000. Effect of interferon beta on human myelin basic protein-specific T-cell lines: Comparison of IFNbeta-1a and IFNbeta-1b. Neurology 55 (2):322–3. 25,
   PubMedGoogle Scholar
• W.I. McDonald, A. Compston, G. Edan, D. Goodkin, H.P. Hartung, F.D. Lublin, H.F. McFarland, D.W. Paty, C.H. Polman, S.C. Reingold, M. Sandberg-Wollheim, W. Sibley, A. Thompson, S. van den Noort, B.Y. Weinshenker, and J.S. Wolinsky. 2001. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (1):121–7.
   PubMed Web of Science ®Google Scholar
• P.B. Carrieri, V. Provitera, T. De Rosa, G. Tartaglia, F. Gorga, and O. Perrella. 1998. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: A correlation with clinical activity. Immunopharmacol. Immunotoxicol. 20 (3):373–82.
   PubMedGoogle Scholar
• C.L. Karp, A.H. van Boxel-Dezaire, A.A. Byrnes, and L. Nagelkerken. 2001. Interferon-beta in multiple sclerosis: Altering the balance of interleukin-12 and interleukin-10?. Curr. Opin. Neurol. 14 (3):361–8.
   PubMedGoogle Scholar
• A. Jansson, J. Ernerudh, M. Kvarnstrom, C. Ekerfelt, and M. Vrethem. 2003. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients. Mult. Sclerosis 9 (5):440–5.
   PubMedGoogle Scholar
• M.E. Duddy, M.A. Armstrong, A.D. Crockard, and S.A. Hawkins. 1999. Changes in plasma cytokines induced by interferon-beta1a treatment in patients with multiple sclerosis. J. Neuroimmunol. 101 (1):98–109.
   PubMedGoogle Scholar
• J.J. Graber, D. Ford, M. Zhan, G. Francis, H. Panitch, and S. Dhib-Jalbut. 2007. Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlations with interferon dose and MRI response. J. Neuroimmunol. 185 (1–2):168–74.
   PubMedGoogle Scholar
• G. Perona-Wright, S.M. Anderton, S.E. Howie, and D. Gray. 2007. IL-10 permits transient activation of dendritic cells to tolerize T cells and protect from central nervous system autoimmune disease. Int. Immunol. 19 (9):1123–34.
   PubMedGoogle Scholar
• K. Ohkuma, T. Sasaki, S. Kamei, S. Okuda, H. Nakano, T. Hamamoto, K. Fujihara, I. Nakashima, T. Misu, and Y. Itoyama. 2007. Modulation of dendritic cell development by immunoglobulin G in control subjects and multiple sclerosis patients. Clin. Exp. Immunol. 150 (3):397–406.
   PubMedGoogle Scholar
• M.S. Weber, T. Prod'homme, S. Youssef, S.E. Dunn, C.D. Rundle, L. Lee, J.C. Patarroyo, O. Stüve, R.A. Sobel, L. Steinman, and S.S. Zamvil. 2007. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat. Med. 13 (8):935–43.
   PubMedGoogle Scholar
• J.J. Graber, D. Ford, M. Zhan, G. Francis, H. Panitch, and S. Dhib-Jalbut. 2007. Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlations with interferon dose and MRI response. J. Neuroimmunol. 185 (1–2):168–74.
   PubMedGoogle Scholar
• L.P. Koopman, H. Savelkoul, I.J. van Benten, J. Gerritsen, B. Brunekreef, and H. J Neijens. 2003. Increased serum IL-10/IL-12 ratio in wheezing infants. Pediatr. Allergy. Immunol. 14 (2):112–9.
   PubMedGoogle Scholar
• A. La Cava, and G. Matarese. 2004. The weight of leptin in immunity. Nat. Rev. Immunol. 4 (5):371–9.
   PubMedGoogle Scholar
• G. Matarese, P.B. Carrieri, A. La Cava, F. Perna, V. Sanna, V. De Rosa, D. Aufiero, S. Fontana, and S. Zappacosta. 2005. Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 102 (14):5150–5. 5,
   PubMedGoogle Scholar
• G. Frisullo, F. Angelucci, M. Mirabella, M. Caggiula, K. Patanella, V. Nociti, P.A. Tonali, and A.P. Batocchi. 2004. Leptin enhances the release of cytokines by peripheral blood mononuclear cells from relapsing multiple sclerosis patients. J. Clin. Immunol. 24 (3):287–93.
   PubMedGoogle Scholar